Abstract: A control device for a hybrid electric vehicle includes an electronic control unit. The electronic control unit is configured to perform a start-up control of shifting the connection and disconnection clutch to a coupled state at the time of starting the internal combustion engine to rotate the internal combustion engine by the driving torque of the electric motor, and starting the first fuel injection mode using the direct injection injector. The electronic control unit is configured to switch from the first fuel injection mode to a second fuel injection mode for using the port injector prior to an end of the start-up control when the number of times of combustion cycles of the internal combustion engine with the first fuel injection mode reaches a predetermined first target number of times.

Abstract: A lithium ion secondary battery includes a negative electrode including a mixture layer which contains a niobium titanium oxide as a negative electrode active material, and non-aqueous electrolyte containing lithium alkoxysulfonate represented by RSOOO?Li+ (where R is at least one selected from the group consisting of OCH3 and OC2H5).

Abstract: A heater element includes: a honeycomb structure including an outer peripheral wall and partition walls disposed on an inner side of the outer peripheral wall, the partition walls defining a plurality of cells, each of the cells extending from a first end face to a second end face to form a flow path; a pair of electrode layers provided on the outer peripheral wall and the partition walls on the first end face and the second end face; and terminals capable of electrically connecting the electrode layers to a conducting wire. At least a part of each of the electrode layers has an extending portion extending outwardly from an outer edge of each of the first end face and the second end face. Each of the terminals is connected to the extending portion and disposed to face a side surface of the honeycomb structure.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: An optical connector device is provided. The optical connector device includes a semiconductor package including a receptacle and a lid. The optical connector device also included an adapter attached to the lid of the semiconductor package, and a connector removably attached to the adapter. The adapter includes a convex part adapted to fit into an adapter opening of the lid, an adapter recess adapted to accommodate at least a portion of the connector, and a first retainer in the adapter recess to removably attach the connector to the adapter at a predetermined position. The connector includes an optical fiber array corresponding to the receptacle and extending in a vertical direction with respect to a plane of the semiconductor package, a second retainer used in conjunction with the first retainer, and a biasing member to bias a portion of the connector toward the semiconductor package.

Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

Abstract: An object of the present invention is to improve the intake efficiency of cannabidiol (CBD). The above object can be achieved by a seamless soft capsule comprising a capsule film, and a content enclosed in the capsule film, wherein the content contains cannabidiol.

Abstract: A rotation detector includes a rotary member, a magnet rotating as the rotary member rotates, and a first magnetic sensor detecting a direction of magnetic flux that changes as the magnet rotates. And the rotation detector includes a first soft magnetic member and a second soft magnetic member for the first magnetic sensor that are arranged on one side and the other side, respectively, of a detection direction of the first magnetic sensor. The magnet has a rotation axis that passes through the magnet.

Abstract: A technique for performing a function by utilizing chemical reactions is disclosed. In the technique, solution including an input chemical species having a concentration is provided. A chemical reaction network that includes at least a sequence of chemical reactions starting with the input chemical species to generate a plurality of output chemical species is also prepared. The solution is exposed to the chemical reaction network to present a pattern formed by the plurality of output chemical species depending on the concentration of the input chemical species.

Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor.

Abstract: An inspection apparatus includes: a light emitter to emit light to a sealing portion of a package containing a light energy absorbing material, the light having a wavelength absorbable by the light energy absorbing material; a light receiver to receive thermal radiation from the sealing portion as thermal information; and circuitry including multiple image processing algorithms, the circuitry to: acquire the thermal information on the sealing portion from the light receiving unit as a two-dimensional image; determine whether the sealing portion is pass or fail based on the two-dimensional image acquired; and discriminate a type of a sealing defect from other types of sealing defects previously set in the multiple image processing algorithms in response to a determination that the sealing portion is fail.

Abstract: Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)?: wherein A is S or O; R1a is substituted or unsubstituted alkyloxy or the like, R2a to R2d are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R3 is each independently halogen or the like, r is an integer of 0 to 4, R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.

Abstract: A communication device includes a transmission unit and a processing unit. The transmission unit transmits a packet group including multiple packets. In a case in which the communication device itself is not trusted by a destination communication device to which to transmit the packet group, the processing unit performs a process of instructing each of multiple nodes of a management unit that registers and manages management information distributed among the multiple nodes to register header information as the management information, the header information being partial information of a header included in each packet of the packet group transmitted by the transmission unit.

Abstract: A rotation detector includes a rotary member, a magnet rotating as the rotary member rotates, and a first magnetic sensor detecting a direction of magnetic flux that changes as the magnet rotates. And the rotation detector includes a first soft magnetic member and a second soft magnetic member for the first magnetic sensor that are arranged on one side and the other side, respectively, of a detection direction of the first magnetic sensor. The magnet has a rotation axis that passes through the magnet.

Abstract: A communication device includes a transmission unit and a processing unit. The transmission unit transmits a packet group including multiple packets. In a case in which the communication device itself is not trusted by a destination communication device to which to transmit the packet group, the processing unit performs a process of instructing each of multiple nodes of a management unit that registers and manages management information distributed among the multiple nodes to register header information as the management information, the header information being partial information of a header included in each packet of the packet group transmitted by the transmission unit.

Abstract: Novel compounds having a D3 receptor antagonistic activity are provided. The compound represented by Formula (I): wherein Ring A is a non-aromatic heterocycle or the like substituted with substituted or unsubstituted aromatic heterocyclyl or the like; R2a to R2d are each independently a hydrogen atom or the like; n is an integer of 0 to 3; Ring B is a non-aromatic carbocycle or the like; R3 is each independently halogen or the like; r is an integer of 0 to 4; -L- is —N(R10)—C(?O), or the like; R10 is a hydrogen atom or the like; R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.

Abstract: An imaging apparatus includes: a board; a recording medium accommodation portion provided on the board and configured to removably accommodate a recording medium; a radiator plate provided at a position away from the recording medium accommodation portion; a thermal conductive sheet including a first portion fixed to the radiator plate and a second portion in contact with the recording medium accommodation portion; a cushion member configured to urge a second portion of the thermal conductive sheet toward the recording medium accommodation portion and to maintain contact between a second portion of the thermal conductive sheet and the recording medium accommodation portion; and a cushion member support member configured to support the cushion member.

Abstract: According to an embodiment, a management system includes a vehicle management device configured to manage parking of a vehicle in a parking space and delivery of the vehicle from the parking space, and a vehicle conveying device configured to be able to convey the vehicle in forward-backward and widthwise directions of the vehicle. The vehicle management device includes a controller configured to control the vehicle conveying device so that the vehicle is conveyed to the parking space when a request for parking the vehicle located within a section where parking in the parking space is able to be requested has been received.

Abstract: An imaging apparatus includes: a board; a recording medium accommodation portion provided on the board and configured to removably accommodate a recording medium; a radiator plate provided at a position away from the recording medium accommodation portion; a thermal conductive sheet including a first portion fixed to the radiator plate and a second portion in contact with the recording medium accommodation portion; a cushion member configured to urge a second portion of the thermal conductive sheet toward the recording medium accommodation portion and to maintain contact between a second portion of the thermal conductive sheet and the recording medium accommodation portion; and a cushion member support member configured to support the cushion member.

Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.